Use of Rivaroxaban and Apixaban, Two Non-Vitamin K Antagonist Oral Anticoagulants (NOACs), in Renally Impaired Patients - the limits of our knowledge
Open Access
- 1 January 2018
- journal article
- Published by Heighten Science Publications Corporation in Journal of Cardiology and Cardiovascular Medicine
- Vol. 3 (3), 049-051
- https://doi.org/10.29328/journal.jccm.1001026
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerationsInternational Journal of Nephrology and Renovascular Disease, 2017
- Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic HemodialysisAmerican Journal of Nephrology, 2016
- Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysisThe Journal of Clinical Pharmacology, 2015
- Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixabanThe Journal of Clinical Pharmacology, 2015
- Edoxaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2013
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationThe New England Journal of Medicine, 2011
- Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorBritish Journal of Clinical Pharmacology, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009